Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 6/20 | 0.50 |
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | CA2 | P00918 | 6/20 | 0.50 |
| ▸ | CA9 | Q16790 | 6/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | STK17B | O94768 | 1/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15680567 | 0.95 | TDP1 (0.64) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL4125770 | 0.93 | TDP1 (0.58) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL34463500 | 0.93 | TDP1 (0.67) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL4120360 | 0.90 | TDP1 (0.54) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL14540437 | 0.89 | CA14 (0.59) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL5217505 | 0.89 | TDP1 (0.54) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL13377000 | 0.89 | TDP1 (0.66) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL1979026 | 0.89 | TDP1 (0.55) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL1931261 | 0.88 | DNM1 (0.61) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL1930544 | 0.88 | DNM1 (0.61) | TDP1MEN1GAAKMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119913158-A | Nucleic acid aptamer with zwitterionic modification and preparation method thereof | 浙江工业大学 | 2025-05-02 | — | — | CN | disclosed |
| EP-3805214-B1 | JAK3 SELECTIVE INHIBITOR | UNIV PEKING SHENZHEN GRADUATE SCHOOL (CN) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023279211-A1 | METAL-CONTAINING POLYMERS FOR MASS CYTOMETRY | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2023-01-12 | — | — | WO | disclosed |
| US-10227333-B2 | Inhibition of OLIG2 activity | Curtana Pharmaceuticals, Inc. (US) | 2019-03-12 | — | — | US | disclosed |
| WO-2018081797-A1 | PERIPHERAL MODIFICATIONS ON POCKET-REDESIGNED VANCOMYCIN ANALOGS SYNERGISTICALLY IMPROVE ANTIMICROBIAL POTENCY AND DURABILITY | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-03 | — | — | WO | disclosed |
| US-9580749-B2 | Dyes and labeled molecules | BIOTIUM, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| CN-103936716-B | Tool muscarinic receptor antagonists and the diamide compound of beta 2 adrenoreceptor agonists activity | 施万呼吸有限责任公司 | 2016-09-07 | — | — | CN | disclosed |
| US-20160237069-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2016-08-18 | — | — | US | disclosed |
| US-20160237069-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2016-08-18 | — | — | US | disclosed |
| US-9102835-B2 | Methods of using dyes in association with nucleic acid staining or detection and associated technology | BIOTIUM, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-7659070-B2 | Charge switch nucleotides | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20100009454-A1 | METHODS OF USING DYES IN ASSOCIATION WITH NUCLEIC ACID STAINING OR DETECTION AND ASSOCIATED TECHNOLOGY | BIOTIUM, INC. | 2010-01-14 | — | — | US | disclosed |
| US-7625701-B2 | Triphosphate having gamma-phosphate with detectable group attached; detection using charge coupled device camera or photodiode; labeled nucleotide phosphate (e.g., gamma -NP-Dye) that on cleavage of phosphate detectable moiety (e.g., PPi-Dye) has different charge compared to intact nucleotide phosphate | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7601498-B2 | Methods of using dyes in association with nucleic acid staining or detection and associated technology | BIOTIUM, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080206764-A1 | Flowcell system for single molecule detection | PACIFIC BIOSCIENCES (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1947105-A1 | Method for single-step attachment of a label to target molecules | Mirus Bio Corporation (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20080153095-A1 | CHARGE SWITCH NUCLEOTIDES | PACIFIC BIOSCIENCES (US) | 2008-06-26 | — | — | US | disclosed |
| US-7326780-B2 | Label (fluorescence-emitting molecule, hapten-containing molecule, protein, or radioactive chemical) attached to N-(2-chloroethyl)-N-methylaminobenzylamino ligand by a spacer forming a neutralized quaternary ammonium group for covalent attachment to DNA, RNA, or siRNA | MIRUS BIO CORPORATION (US) | 2008-02-05 | — | — | US | disclosed |
| US-20060211028-A1 | Dimeric and trimeric nucleic acid dyes, and associated systems and methods | ALLELOGIC BIOSCIENCES CORPORATION | 2006-09-21 | — | — | US | disclosed |
| US-20060211029-A1 | Methods of using dyes in association with nucleic acid staining or detection and associated technology | BIOTIUM, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211028-A1 | Dimeric and trimeric nucleic acid dyes, and associated systems and methods | DNA2, POLRMT, POLL | TDP1 105/4885MEN1 3398/4885GAA 544/4885 |
| US-10227333-B2 | Inhibition of OLIG2 activity | GLI2, ING2, GMFG | TDP1 3233/4885MEN1 2974/4885GAA 2405/4885 |
| US-20060211029-A1 | Methods of using dyes in association with nucleic acid staining or detection and associated technology | HNRNPLL, HNRNPL, HNRNPH3 | TDP1 287/4885MEN1 3185/4885GAA 1454/4885 |
| US-20160237069-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | TDP1 3233/4885MEN1 2974/4885GAA 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.